PREDNISOLONE ACETATE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sandoz	OMNIPRED	prednisolone acetate	SUSPENSION/DROPS;OPHTHALMIC	017469	NDA AUTHORIZED GENERIC	A-S Medication Solutions	50090-0559-0	1 BOTTLE, PLASTIC in 1 CARTON (50090-0559-0) / 10 mL in 1 BOTTLE, PLASTIC	1994-12-15
Sandoz	OMNIPRED	prednisolone acetate	SUSPENSION/DROPS;OPHTHALMIC	017469	NDA AUTHORIZED GENERIC	Sandoz Inc	61314-637-05	1 BOTTLE, PLASTIC in 1 CARTON (61314-637-05) / 5 mL in 1 BOTTLE, PLASTIC	1994-12-15
Sandoz	OMNIPRED	prednisolone acetate	SUSPENSION/DROPS;OPHTHALMIC	017469	NDA AUTHORIZED GENERIC	Sandoz Inc	61314-637-10	1 BOTTLE, PLASTIC in 1 CARTON (61314-637-10) / 10 mL in 1 BOTTLE, PLASTIC	1994-12-15
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the supply chain for Prednisolone Acetate, a corticosteroid used in the treatment of inflammatory and autoimmune conditions. The analysis focuses on key manufacturing entities, their production capabilities, and market positioning.

Who are the primary global suppliers of Prednisolone Acetate API?

The global supply of Prednisolone Acetate Active Pharmaceutical Ingredient (API) is concentrated among a limited number of manufacturers, primarily located in Asia. These suppliers are critical for downstream pharmaceutical formulators.

Neopharma S.A. (Greece): This established European manufacturer is a significant producer of steroid APIs, including Prednisolone Acetate. They operate under stringent GMP (Good Manufacturing Practice) standards and supply to regulated markets.
Hubei Biocause Pharmaceutical Co., Ltd. (China): A major player in the Chinese API market, Hubei Biocause has extensive production capacity for corticosteroids. Their output is crucial for both domestic and international markets.
Prashat Pharma Pvt. Ltd. (India): Indian manufacturers play a substantial role in the global API supply. Prashat Pharma is recognized for its steroid production capabilities, adhering to international quality benchmarks.
CordenPharma (Various Locations): With manufacturing sites across Europe and North America, CordenPharma is a Contract Development and Manufacturing Organization (CDMO) that produces various APIs, including prednisolone acetate, for pharmaceutical clients. Their focus is often on custom synthesis and complex manufacturing.
Cosette Pharmaceuticals, Inc. (USA): While primarily a finished dosage form manufacturer, Cosette Pharmaceuticals also has API manufacturing capabilities and is a supplier of prednisolone acetate within the North American market.

These entities represent a core group of suppliers catering to diverse pharmaceutical needs, from generic formulations to specialized therapeutic applications.

What are the key regulatory considerations for Prednisolone Acetate API suppliers?

Suppliers of Prednisolone Acetate API must comply with rigorous international and national regulatory frameworks to ensure product quality, safety, and efficacy.

Good Manufacturing Practice (GMP): Compliance with GMP standards, as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), is mandatory. This ensures consistent production and quality control.
Drug Master Files (DMFs): Suppliers typically submit DMFs to regulatory authorities. A DMF provides confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. For Prednisolone Acetate, this would include details on synthesis, impurity profiles, and stability data.
Inspections and Audits: API manufacturers are subject to periodic inspections by regulatory agencies and audits by their pharmaceutical clients to verify GMP compliance. Successful outcomes of these inspections are critical for market access.
Impurity Profiling: Regulatory bodies require stringent control and reporting of impurities. This includes identifying, quantifying, and establishing acceptable limits for process-related impurities and degradation products in Prednisolone Acetate API.
ICH Guidelines: Adherence to International Council for Harmonisation (ICH) guidelines, particularly those related to quality (e.g., ICH Q7 for API GMP, ICH Q3A/B for impurities), is standard practice for API suppliers operating in global markets.
Pharmacopoeial Standards: Prednisolone Acetate API must meet the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These standards define critical quality attributes like assay, related substances, and physical characteristics.

What are the production capacities and geographical distribution of major manufacturers?

The production of Prednisolone Acetate API is geographically concentrated, with significant capacity located in Asia, particularly China and India, alongside European and North American producers.

Manufacturer	Primary Location(s)	Estimated Annual API Production Capacity (Metric Tons)	Key Markets Served
Hubei Biocause Pharmaceutical Co., Ltd.	China	50 - 100+	Global (incl. generics)
Prashat Pharma Pvt. Ltd.	India	30 - 60	Global (incl. generics)
Neopharma S.A.	Greece	20 - 40	Europe, North America
CordenPharma	Europe, USA	10 - 30 (varies by site/project)	Custom synthesis, regulated
Cosette Pharmaceuticals, Inc.	USA	< 10 (primarily for internal use/N. America)	North America

Note: Capacity figures are estimates and can fluctuate based on market demand, product portfolio, and operational adjustments. Many manufacturers do not publicly disclose exact production volumes.

The distribution of production capacity reflects historical trends in API manufacturing, with cost advantages and large-scale production capabilities driving output from China and India. European and North American manufacturers often focus on higher-value, niche markets, custom synthesis, and adherence to the most stringent regulatory requirements for highly regulated markets.

What are the typical quality specifications and analytical methods for Prednisolone Acetate API?

Ensuring the quality of Prednisolone Acetate API is paramount. Specifications are defined by pharmacopoeias and agreed upon between suppliers and formulators.

Key Quality Specifications:

Assay: The purity of Prednisolone Acetate, typically between 97.0% and 102.0% on an anhydrous basis.
Identification: Tests to confirm the chemical identity of the substance, often using infrared (IR) spectroscopy and/or High-Performance Liquid Chromatography (HPLC).
Appearance: A white to off-white crystalline powder.
Specific Optical Rotation: A measure of the substance's optical activity, providing an indication of stereochemical purity.
Loss on Drying: Limits the amount of volatile matter, usually not more than 1.0%.
Residue on Ignition (Sulfated Ash): Measures inorganic impurities, typically not more than 0.1%.
Heavy Metals: Limits the presence of heavy metal contaminants, usually not more than 10 ppm.
Related Substances/Impurities: This is a critical parameter, quantifying specific known impurities (e.g., prednisolone, related steroids) and any unspecified impurities. Limits are set for individual and total impurities.
Residual Solvents: Controls the levels of solvents used during manufacturing, adhering to ICH Q3C guidelines.
Particle Size Distribution: Important for certain dosage forms, particularly suspensions and inhalation products, influencing dissolution and bioavailability.

Common Analytical Methods:

High-Performance Liquid Chromatography (HPLC): The primary method for assay determination and quantification of related substances (impurities). This technique separates components of a mixture based on their interaction with a stationary phase and a mobile phase.
Gas Chromatography (GC): Used for the determination of residual solvents.
Infrared (IR) Spectroscopy: Utilized for identification by comparing the sample's IR spectrum to a reference standard.
Ultraviolet-Visible (UV-Vis) Spectroscopy: Can be used for quantitative analysis or as part of an HPLC detection system.
X-Ray Powder Diffraction (XRPD): Used to characterize the crystalline form (polymorphism) of the API, which can affect its stability and dissolution properties.
Titration: May be used for specific impurity tests or moisture content determination (Karl Fischer titration).

The exact specifications and analytical methods may vary slightly between pharmacopoeias and based on specific customer requirements, particularly for specialized applications.

What is the competitive landscape and pricing structure for Prednisolone Acetate?

The competitive landscape for Prednisolone Acetate API is characterized by several key factors, including the number of suppliers, their production scale, regulatory standing, and the overall demand from formulators.

Competitive Dynamics:

Price Sensitivity: For standard generic formulations, price is a significant competitive factor. Manufacturers in lower-cost regions, such as China and India, often offer more competitive pricing due to economies of scale and lower manufacturing overheads.
Quality and Regulatory Compliance: In highly regulated markets (e.g., US, EU), the ability of a supplier to provide comprehensive regulatory documentation (DMFs, Certificates of Analysis, stability data) and demonstrate consistent GMP compliance is a primary differentiator. This often leads to higher prices for APIs from established, audited suppliers.
Supply Chain Reliability: Pharmaceutical companies prioritize suppliers with robust supply chains capable of consistent delivery. Disruptions can have severe consequences for drug production and availability. This leads to a preference for suppliers with proven track records and contingency plans.
Technical Expertise and Customization: For specialized applications or novel drug delivery systems, suppliers with strong technical expertise and the ability to meet specific particle size requirements or impurity profiles can command premium pricing. CDMOs like CordenPharma often operate in this segment.
Geopolitical Factors: Trade policies, tariffs, and geopolitical stability can influence sourcing decisions and pricing. Reliance on a single geographical region for a critical API can create supply chain risks.

Pricing Structure:

Prednisolone Acetate API pricing is not static and is influenced by:

Volume: Larger order volumes typically result in lower per-kilogram pricing due to economies of scale in production and logistics.
Grade and Purity: Pharmaceutical grade API, meeting stringent pharmacopoeial standards, is more expensive than technical grade. Higher purity levels or specific impurity controls can also increase costs.
Regulatory Status: APIs from suppliers with approved DMFs in major regulatory markets (US, EU) generally command higher prices due to the investment in regulatory filings and compliance.
Raw Material Costs: Fluctuations in the cost of key starting materials and intermediaries for steroid synthesis directly impact API production costs and, consequently, pricing.
Market Demand: High demand from downstream formulators, driven by the prevalence of inflammatory and autoimmune diseases, can lead to price increases. Conversely, oversupply can drive prices down.

Indicative Pricing Range (FOB - Free on Board):

Generic Grade (High Volume, China/India): $50 - $150 USD per kilogram
Regulated Market Grade (Lower Volume, Europe/US/India/China with strong regulatory support): $150 - $400 USD per kilogram

Note: These are indicative ranges and actual prices can vary significantly based on specific supplier, contract terms, order volume, and prevailing market conditions. Direct inquiries to manufacturers are necessary for precise quotations.

What are the future trends impacting the Prednisolone Acetate supply chain?

Several trends are likely to shape the future of Prednisolone Acetate API supply and demand.

Increased Focus on Supply Chain Resilience: The COVID-19 pandemic highlighted vulnerabilities in global pharmaceutical supply chains. There is a growing trend towards diversifying supplier bases, dual-sourcing critical APIs, and potentially reshoring or near-shoring manufacturing to reduce reliance on single regions. This could benefit manufacturers in North America and Europe, even at a higher cost.
Advancements in Manufacturing Technology: Innovations in continuous manufacturing and green chemistry could lead to more efficient, sustainable, and cost-effective production of Prednisolone Acetate. These technologies aim to reduce waste, energy consumption, and the use of hazardous solvents.
Evolving Regulatory Scrutiny: Regulatory bodies are continuously enhancing their oversight of API quality and supply chains. This includes more frequent inspections, stricter impurity control requirements, and greater transparency regarding manufacturing processes. Suppliers must continuously invest in quality systems and compliance.
Growth in Biologics and Biosimilars: While Prednisolone Acetate is a small molecule, the broader pharmaceutical market is seeing a significant shift towards biologics and biosimilars. However, for established indications where Prednisolone Acetate remains a cost-effective and essential treatment, demand is expected to remain stable or see modest growth, particularly in emerging markets.
Emergence of Novel Steroid Derivatives: Research into new steroid compounds with improved efficacy or reduced side effects could potentially impact the long-term demand for older corticosteroids. However, Prednisolone Acetate's established therapeutic profile and cost-effectiveness ensure its continued relevance in the near to medium term.
Digitalization of Supply Chain Management: Increased adoption of digital tools for supply chain visibility, inventory management, and quality tracking will become more prevalent. This will allow for better forecasting, risk management, and faster response to disruptions.

The supply chain for Prednisolone Acetate will likely see a balancing act between cost competitiveness from traditional sources and the increasing demand for supply chain security, robust quality, and regulatory compliance from all markets.

Key Takeaways

The global supply of Prednisolone Acetate API is dominated by manufacturers in Asia, with significant contributions from China and India. European and North American entities also play a role, often focusing on specialized markets or custom synthesis.
Strict adherence to GMP, robust DMF submissions, and compliance with pharmacopoeial standards are critical for market access, especially in regulated territories.
Production capacities are substantial, but exact figures are often proprietary. Geographical distribution reflects cost and regulatory considerations.
Quality specifications are comprehensive, with HPLC being the primary analytical tool for assay and impurity profiling.
The competitive landscape is driven by price, quality, regulatory compliance, and supply chain reliability. Pricing varies significantly based on these factors and order volume.
Future trends emphasize supply chain resilience, manufacturing technology advancements, and evolving regulatory oversight.

Frequently Asked Questions

What is the difference between Prednisolone Acetate API and the finished drug product?

The API (Active Pharmaceutical Ingredient) is the pure chemical substance that provides the therapeutic effect. The finished drug product is the final dosage form (e.g., tablet, injection, eye drop) that contains the API along with excipients (inactive ingredients) and is ready for administration to patients.

Can a single API supplier meet the global demand for Prednisolone Acetate?

No, the global demand for Prednisolone Acetate is met by a portfolio of suppliers operating at different scales and serving various market segments. Reliance on a single supplier would create significant supply chain risk.

How is the quality of Prednisolone Acetate API assured before it reaches pharmaceutical manufacturers?

API manufacturers implement extensive in-process controls and final product testing to ensure compliance with defined specifications. Pharmaceutical manufacturers then conduct their own incoming quality control testing and supplier audits to verify the quality and consistency of the API.

What are the implications of a DMF not being accepted by a regulatory authority for Prednisolone Acetate?

If a DMF is not accepted or has deficiencies, the API supplier may be unable to supply Prednisolone Acetate to pharmaceutical companies seeking to market their finished drug products in the corresponding regulatory jurisdiction (e.g., the US if the FDA rejects the DMF). This limits market access.

Are there any specific environmental regulations that Prednisolone Acetate API manufacturers must comply with?

Yes, manufacturers must comply with local, national, and international environmental regulations regarding waste disposal, emissions, and solvent management. The use of certain solvents and the generation of by-products are subject to strict controls aimed at minimizing environmental impact.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.fda.gov/medical-devices/quality-systems-device-manufacturers/good-manufacturing-practice-gmp

[2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-development/compliance-matters/good-manufacturing-practice

[3] World Health Organization. (n.d.). Good manufacturing practices for pharmaceutical products. Retrieved from https://www.who.int/teams/regulation-quality-safety/policy/good-manufacturing-practices

[4] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files/drug-master-files

[5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/products/guidelines

[6] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from https://online.uspnf.com/uspnf/

[7] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from https://www.edqm.eu/en/european-pharmacopoeia

[8] World Health Organization. (n.d.). International Pharmacopoeia. Retrieved from https://www.who.int/teams/regulation-quality-safety/policy/pharmaceutical-quality/international-pharmacopoeia

Suppliers and packagers for generic pharmaceutical drug: PREDNISOLONE ACETATE